Randomized Trial of Lenalidomide Alone Versus Lenalidomide Plus Rituximab in Patients With Recurrent Follicular Lymphoma: CALGB 50401 (Alliance). [electronic resource]
Producer: 20160314Description: 3635-40 p. digitalISSN:- 1527-7755
- Adult
- Aged
- Aged, 80 and over
- Antineoplastic Combined Chemotherapy Protocols -- therapeutic use
- Aspirin -- therapeutic use
- Disease Progression
- Disease-Free Survival
- Female
- Heparin -- therapeutic use
- Humans
- Kaplan-Meier Estimate
- Lenalidomide
- Lymphoma, Follicular -- drug therapy
- Male
- Middle Aged
- Neoplasm Recurrence, Local
- Risk Factors
- Rituximab -- administration & dosage
- Thalidomide -- administration & dosage
- Thrombosis -- complications
- Treatment Outcome
No physical items for this record
Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural
There are no comments on this title.
Log in to your account to post a comment.